p Did Nasa astronauts Neil Armstrong and Buzz Aldrin really walk on the moon in 1969, or was it part of an elaborate ruse directed by Stanley Kubrick?Are aircraft leaving 'chemtrails' in the sky, chemical agents sprayed for mysterious and nefarious purposes?Is there actually a cure for cancer, suppressed by pharmaceutical companies in order to protect valuable 'alternative' medicines?Unfortunately for the more imaginative conspiracy theorists among us, the answer to all of these questions is likely to be a resounding no.The equation, which has been published in Plos One, is made up of three factors: the number of conspirators involved, how much time has passed since the alleged conspiracy took place, and the "intrinsic probability of a conspiracy failing".This intrinsic measure was estimated by looking at data from conspiracies that had later been revealed to be true – the PRISM surveillance program, which was revealed by Edward Snowden after several years, the Tuskegee syphilis scandal, which withheld the cure for syphilis from African-Americans and was revealed after 25 years, and an FBI scandal which led to the execution of innocent people, unveiled by a doctor after six years.
The search engine compares the semantic language – the real meaning of the content – in the documents to reveal unseen patterns and connections in fractions of a second.I saw a demo of the platform in January at the Consumer Electronics Show in Las Vegas, and it has a lot of interesting potential.Omnity s basic search is still free, but its subscription packages and special information databases start at $100.The specialized information that Omnity is offering includes Securities and Exchange Commission filings and records, patents, Library of Congress data, court precedents and legal records, scientific journals, pharmaceutical and biomedical trials, financial reports, and U.S. Congress reports and legal history.Discovering unexpected connections between diverse knowledge domains reveals unique insights that sharpen focus and drive innovation.We created Omnity to help scientists, engineers, medical professionals, lawyers and financial people cope with the explosion of data and knowledge that is happening in every field of study.Omnity is designed to be powerful yet easy to use, and is priced so that organizations large and small can access this transformative technology.Unlike conventional search, Omnity said it can find related documents even when they do not cite or link to one another.The company is offering introductory pricing of its commercial service in five tiers, with the first month free for all paid tiers:
Foundation Medicine, a company that got its start with backing from Google Ventures, Bill Gates, and other major tech investors, received a patent this morning that protects its cancer genomic sequencing process.Now, it's using that patent to sue a competitor, Guardant Health."We certainly intend to pursue the value of this patent, we also have always been focused on and remain focused on a very patient-centric mission," Foundation President Steve Kafka told Business Insider on Tuesday."So our intent here is not to block other laboratories from their testing ... but really to develop strategies to recognize the value that we've captured or we've created, rather.Guardant declined to comment on the patent.Cancer genome sequencingWhen people are diagnosed with cancer, there's a pretty standard course of treatment to fight off the disease: the doctor may start with surgery or a regimen of drugs that are known to work on a particular type of cancer.But after a while, if that first round doesn't knock out all the cancer cells, the cancer can come back and be even trickier to treat.Those harder to treat and rare cancers is where cancer genomics companies, including Foundation Medicine, are trying to help.And earlier this month, the company launched its liquid biopsy test, which looks for circulating tumor DNA in the blood.That data also goes into a Foundation Medicine database, where people ranging from doctors looking for methods to treat a certain rare cancer to pharmaceutical companies interested in finding the patients who will respond the best to a drug that's in development could look at it.NOW WATCH: Only in San Francisco — inside the 232-square-foot micro apartment that sold for nearly $425,000Loading video...
A Hong Kong regulator has pointed the finger at Alibaba for breaching acquisition rules when it purchased a healthcare company two years ago, saying the Chinese e-commerce company bought the firm on favorable terms due to a connection with the company s executives.Alibaba purchased CITIC 21 CN in 2014 for $170 million USD, which has since been restructured under Alibaba Health Information Technology Ltd.According to a ruling from the the Takeovers and Mergers Panel of the Hong Kong Securities And Futures Commission posted on Wednesday, Alibaba also purchased another medical technology firm at the time, Hebei Huiyan Medical Technology Co., which was owned by the brother of CITIC 21 CN s vice chairman.The regulator has accused Alibaba of purchasing the second company under favorable conditions, meaning the same deal was not made available to other shareholders.The deal constituted a special deal with favourable conditions which were not extended to all shareholders and was a clear breach of the Takeovers Code, said the result published by the Takeovers and Mergers Panel of the Hong Kong Securities And Futures Commission.The acquisition of CITIC 21 CN left many onlookers scratching their heads back in 2014, when the company was operating at a significant loss.One of the primary benefits of the deal for Alibaba was CITIC 21 CN s large pharmaceutical data base.In July 2014 Alibaba announced they had integrated the company s data to their own e-commerce platform, forming the backbone of their Drug Safety Program , which was launched to clean their e-commerce platforms of fake drugs.Last month when the initial ruling was announced Alibaba said that they would contest the outcome.Alibaba transferred their pharmacy business into Alibaba Health in April last year, consolidating their two biggest health investments.The health arm now oversees the sale of pharmacy products as well as other data-driven healthcare projects.
The serious and sometimes fatal superbug MRSA may have finally met its match from one of the most unlikeliest of places.USF chemistry professor Dr. Bill Baker worked on discovering the chemical explained saying: When we screened darwinolide against MRSA we found that only 1.6 percent of the bacterium survived and grew.MRSA is uniquely dangerous because it can cause a whole range of infections from skin infections to pneumonia and endocarditis.As it has become increasingly clear that the pharmaceutical industry is struggling to keep up with the development of new antibiotics, scientists have started looking at the ends of the Earth for new naturally produced antibiotics that could fight these infections.Shutterstock / isak55 Soil could hold the key to finding the next generation of powerful antibiotics.By searching in nature there is already hope that scientists can find hundreds of new naturally produced antibiotics which can combat the evolving bacteria.
Methicillin Resistant Staphylococcus Aureus Mrsa BacteriaPharmaceutical companies and governments need to provide $40 billion £27.32bn to help tackle deaths caused by antibiotic resistance, a major review has urged.Lord Jim O'Neill, who has led an 18 month research group on drug resistance, has said people should stop treating antibiotics as "sweets" as he presented the findings of his work.The antimicrobial resistance AMR review has put forward 29 recommendations to combat deaths caused by the growing threat.To aid the development of new antibiotics, O'Neill proposed that pharmaceutical companies should contribute to the costs of measures to tackle the problems.He said there should be a "surcharge on the rest of the industry that chooses not to play" and that "we think that is an option that should be given serious attention from policy makers".By 2020 there should be ways for trained specialists, although not necessarily doctors, to be able to diagnose someone through their DNA using smartphones or other handheld devices, added O'Neill.
Shumlin is expected to decide on whether to sign by early next month.The bill was inspired by the recent rage-inducing trend among pharmaceutical companies to dramatically up the price of drugs without clear reasoning—beside price gouging.Shkreli has since stepped down from Turing and currently faces several criminal charges unrelated to drug pricing, but he became a poster-child for the greed of the pharmaceutical industry.The makers of those drugs would then be required to justify the increases to the state s attorney general s office using financial data and manufacturing cost breakdowns.However, it's currently unclear how justifications will be judged by the state.Currently, none are as far along as Vermont's.
To celebrate the millennium he was originally promised at least 100,000, a pair for every day of the 300 years he hoped to reign.But when the huge chests were delivered to his palace, he found only 20,000, and even those were padded out with huge bales of junk material.When the ambitious project to read 'The Book of Life' was launched way back in 1987 politicians and research administrators were indeed persuaded that we would identify hundreds of new therapeutic targets.And it is certainly true that sequencing the genomes of many species has greatly illuminated our understanding of evolutionary biology.The output of the pharmaceutical industry has declined to become pitifully small while the investment has ballooned enormously.Most are complex interactions involving many components in networks that extend in the body well beyond the genome.
Heikki Saukkomaa/Lehtikuva via AP FINLAND OUTHELSINKI AP — American biochemical engineer Frances Arnold, whose discoveries in "directed evolution" have helped produce medicines, including drugs for treating diabetes, on Tuesday was awarded this year's euro 1 million $1.2 million Millennium Technology Prize.The 59-year-old professor of chemical engineering, bioengineering and biochemistry at the California Institute of Technology in Pasadena, was cited for "groundbreaking work that has a great impact on areas such as pharmaceuticals and gene therapy," with hundreds of laboratories and companies around the world using methods she developed, committee chairman Jarl-Thure Eriksson said."Directed evolution, which mimics natural evolution to create new and better proteins in the laboratory, uses the power of biology and evolution to solve many important problems, often replacing less efficient and sometimes harmful technologies," the citation said.Crowdsourcing, problem-solving — nature's been doing that for several billion years," she said.Past winners include Tim Berners-Lee for inventing the World Wide Web, Shuji Nakamura, the inventor of bright blue and white LEDs, and ethical stem-cell pioneer Shinya Yamanaka.The previous winner, in 2014, was British-American physicist Stuart Parkin for discoveries leading to a thousand-fold increase in digital data storage on magnetic disks used in large data centers, cloud services, social networks and downloads of music and film online.
MoreFrench multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016.REUTERS/Philippe Wojazer/File PhotoBy Ben Hirschler and Greg Roumeliotis Reuters - French drugmaker Sanofi named eight candidates to replace the entire board of Medivation Inc on Wednesday, stepping up pressure on the U.S. cancer drug company which has rejected its $9.3 billion 6.3 billion pounds takeover approach."HAND-PICKED NOMINEES"Sanofi's nominees for Medivation's board are Michael Campbell, Barbara Deptula, Wendy Lane, Ronald Rolfe, Steven Shulman, Charles Slacik, James Tyree and David Wilson -- a roster of independent candidates with experience in the drug industry, finance and the law.Campbell led Arch Chemicals, before it was sold to Lonza in 2011 for $1.2 billion, while Deptula headed corporate development at Shire .If that is accurate, we cannot see how you have not done so with us," he wrote.Sanofi wants Medivation - which sells a successful prostate cancer drug called Xtandi and has others in development - to expand in the lucrative oncology sector, as it seeks new businesses to compensate for flagging diabetes revenues.
After years of clinical nursing I moved to work in research, specifically clinical trials of new drugs being developed for rare, life limiting and life threatening diseases.During that I time I got increasingly frustrated with how clinical trials were being conducted.A legislation that forces pharmaceutical companies to consider the needs of children when developing new drugs.During my six years at the EMA I greatly enjoyed the global scientific discussions, and noticed a great shift in mind-set that children should be protected through research, and not protected from research.This moves away from relaying on sterile, snap shot assessments during clinic visits to continuous, real-time data at home, school, with friends and family.Our approach in aparito underpins the emerging needs of all aspects of healthcare.
You will soon be able to 3D print all your medication into a customised super pill, if this latest research is anything to go by.Scientists at the National University of Singapore NUS have developed a new technology that combines multiple pills of varying dosages into a single tablet.The pills have time-release factored in as well, which means the drugs are released in the body in pulses rather than in one go.View photosMoreAssistant professor Soh Siow Ling, right, with PhD student Sun Yajuan NUS For a long time, personalised tablets has been a mere concept as it was far too complex or expensive to be realised, said assistant professor Soh Siow Ling – one of the researchers involved in the project.Each component is a specifically designed shape separated by a polymer that will determine when the drug is released into the body and in what dosage.The method essentially requires doctors to map out all the medications their patients need to take, the doses they require and the time they need to take them.
Cyber war is on the rise, from Russian cyber soldiers knocking out the power grid in Ukraine to Iranian hackers compromising American dams to Chinese agents stealing trade secrets from U.S. defense, technology, and pharmaceutical companies to say nothing of the theft of millions of records from the Office of Personnel Management .Catastrophe bonds solve this problem by securitizing the risk and passing it on to a wide pool of investors.Before launching an attack against a foreign company, Vladimir Putin would have to worry about erasing billions of dollars from his own country s pension funds, possibly leading to riots in the streets.Nor did it stop his domestic approval rating from jumping 20-points.Countries may lack the political will to share threat intelligence about foreign cyber attacks, root out cyber criminals, or work through international organizations to bolster cyber security.Additionally, nothing about Cyber Bonds supersedes existing treaties or takes the option of military retaliation off the table.
Sweden, seasonally adjusted industrial production growth in April to 3.5% last year compared to April, the country's statistics authority told reporters on Friday.compared with March growth came to 0.1%.during the Month, the highest growth in the chemical and pharmaceutical industry, where the rise came to 21.9%.compared with March, the largest reduction came in the electronics sector.to refine the data according to the country's industrial production increased in march to 5.6 per cent last year compared with march.
Photo: ROBERT ÖRTHENRecommendations: Funding for students in the first university year given tips if you don't think of any other use student loans, then buy your Orion shares will probably remain otherwise qualified, except Orion.Funding for students in the first university year given tips if you don't think of any other use student loans, then buy your Orion shares will probably remain otherwise qualified, except Orion.the pharmaceutical company Orion has traditionally valued the stock market for its good dividend payment capacity.Parkinson's medicines the sale has dropped the patent expires in 2011, and new hit products can be expected at the earliest in 2019.Own product sales will not increase for at least the next few years, and novelty items associated with significant uncertainty , Sarkamies explain.Positive buy recommendation of orion's stock has recently given only yhdysvalta-investment bank Jefferies.
in Oulu, has developed a method by which the autograft may be replaced by a reindeer bone contained pasta time extracts.the Surgeon injects the paste-like implant in open or endoscopic surgery is required towards the bone.bone deficiency or bone a period of consolidation in the disorder of the treatment necessary and cut those patients is estimated at a thousand a year, but the world the need is really great , told orthopedics and traumatology professor Pekka noble danger from the university of Oulu.reindeer bone containing extract tests and exams are nearing and a marketing authorisation is sought for next year.BB-Bioactive Bone Substituted Oy had already last year a pharmaceutical company permission to reindeer bone so called.It can be obtained a noble risk, according to the result of more than two weeks, complex chemical process.
Photo: Flickr/Christina Tu, Sue & Bill Gross Stem Cell Research CenterUntil now, the second-largest acquisition in the history of venture capital was largely based on clinical-trial data that hadn't been released.In data released Sunday at the American Society of Clinical Oncology conference, Stemcentrx showed that its drug could extend the lives of certain patients with small-cell lung cancer.The Phase 1 study released Sunday, which had the goal of showing that Rova-T is effective and safe to use, looked at 74 people with small-cell lung cancer whose disease had gotten worse even with at least one other treatment option.Although these results are preliminary, rovalpituzumab tesirine seems to be the first targeted therapy to show efficacy in small cell lung cancer, and we may have identified DLL3 as the first predictive biomarker in this disease, Dr. Charles Rudin, an oncologist at Memorial Sloan Kettering who led the study, said in a release.What's nextSan Francisco-based Stemcentrx, which has been working on its drugs since 2008 but only launched publicly in September 2015.Since the acquisition by AbbVie, according to CEO Brian Slingerland, not much has changed in the day-to-day operations.
http://www.c-span.org/video/?404183-1/hearing-prescription-drug-marketMartin Shkreli, the infamous ex-pharmaceutical executive known for hiking the price of a life-saving drug, pled not guilty Monday to yet another criminal charge.The charge stems from an alleged Ponzi-like scheme in which he swindled his former pharmaceutical company, Retrophin, out of millions to cover losses of two failing hedge funds he managed.Matsumoto agreed, ordering the defendants back to court July 14 to set a trial date, possibly for sometime in early 2017.On his way out, Shkreli smirked and used the popular social media app, Periscope, to live broadcast his return home, including a stop at Dunkin Donuts.There, another customer at the restaurant recognized Shkreli and asked how the hearing went, to which Shkreli replied: It went great, the judge bitch-slapped the government, again.The charges Shkreli faces carry a maximum sentence of 20 years.
Verily defended itself with a version of the oft-heard Silicon Valley mantra that we choose to do things because they are hard and then added on that some projects can and will fail.In this case, Novartis, a major pharmaceutical company, even partnered with Google to license the technology.Silicon Valley arrogance is nothing new let s not forget the whole Theranos fall from grace .But because GoogleX s other ideas—like the self-driving cars—sounded weird at first and have turned out to really move the dial, it s easy to have high hopes for all their promises.A couple months ago, Google even patented a device that would be injected directly into your eye.But, much as we might hope otherwise, Google can t exactly win in a war against science, and it looks like we ll have to continue monitoring our blood sugar the old-fashioned and less cool way.
Thomas Nevanperä examines the University of Oulu, environmental and chemical engineering VOC laboratory, discovered how harmful industrial emissions of odorous gases react with different catalysts, and they can be destroyed or used up the benefit. Some of the smoky smell is clearly stronger materials that promote climate change greenhouse gases than a lot of the present carbon dioxide. - Some of these gases to climate warming potential, however, a significantly higher proportion of carbon dioxide. Nevanperä is involved in research group that studies the University of Oulu, environmental and chemical engineering research unit means to reduce the harmful smell gas industry. The forest industry, in addition to harmful gas emissions will also be, for example, the chemical and pharmaceutical industry, landfills and water treatment. The end result is either less dangerous and easier to handle substances or chemicals that can even be taken for reuse.